{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:14:57Z","timestamp":1793999697364,"version":"4.8.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,16]],"date-time":"2019-06-16T00:00:00Z","timestamp":1560643200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,16]],"date-time":"2019-06-16T00:00:00Z","timestamp":1560643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13256-019-2071-2","type":"journal-article","created":{"date-parts":[[2019,6,16]],"date-time":"2019-06-16T00:02:23Z","timestamp":1560643343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1315-4127","authenticated-orcid":false,"given":"Luiz Augusto","family":"Casulari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Faria","family":"de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iruena Moraes","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luiz","family":"Mendon\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"de F\u00e1tima Magalh\u00e3es Gonzaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,16]]},"reference":[{"key":"2071_CR1","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/BF03346388","volume":"31","author":"L Vilar","year":"2008","unstructured":"Vilar L, Freitas MC, Naves LA, Casulari LA, et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Investig. 2008;31:436\u20134.","journal-title":"J Endocrinol Investig"},{"issue":"2","key":"2071_CR2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.20945\/2359-3997000000032","volume":"62","author":"L Vilar","year":"2018","unstructured":"Vilar L, Abucham J, Albuquerque JL, Araujo LA, et al. Controversial issues in the management of hyperprolactinemia and prolactinomas - an overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2018;62(2):236\u201363.","journal-title":"Arch Endocrinol Metab"},{"key":"2071_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11060-013-1270-8","volume":"117","author":"ME Molitch","year":"2014","unstructured":"Molitch ME. Management of medically refractory prolactinoma. J Neurooncol. 2014;117:421\u20138.","journal-title":"J Neurooncol"},{"key":"2071_CR4","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3171\/2010.11.JNS101369","volume":"114","author":"MC Oh","year":"2011","unstructured":"Oh MC, Aghi MK. Dopamine agonist-resistant prolactinomas: a review. J Neurosurg. 2011;114:1369\u201379.","journal-title":"J Neurosurg"},{"key":"2071_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-12-0236","volume":"167","author":"L Vroonen","year":"2012","unstructured":"Vroonen L, Jaffrain-Rea ML, Petrossians P, et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012;167:651\u201362.","journal-title":"Eur J Endocrinol"},{"key":"2071_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1046\/j.1365-2265.1999.00748.x","volume":"51","author":"J Feldkamp","year":"1999","unstructured":"Feldkamp J, Santen R, Harms E, Aulich A, Modder U, Scherbaum WA. Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas \u2013 results of a prospective study. Clin Endocrinol. 1999;51:109\u201313.","journal-title":"Clin Endocrinol"},{"key":"2071_CR7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1677\/ERC-08-0170","volume":"15","author":"GA Kaltsas","year":"2008","unstructured":"Kaltsas GA, Evanson J, Chrisoulidou A, Grossman AB. The diagnosis and management of parasellar tumours of the pituitary. Endocr Relat Cancer. 2008;15:885\u2013903.","journal-title":"Endocr Relat Cancer"},{"key":"2071_CR8","doi-asserted-by":"publisher","first-page":"R171","DOI":"10.1530\/EJE-15-1272","volume":"175","author":"V Vasilev","year":"2016","unstructured":"Vasilev V, Rostomyan L, Daly AF, et al. Management of endocrine disease: pituitary \u201cincidentaloma\u201d: neurological assessment and differential diagnosis. Eur J Endocrinol. 2016;175:R171\u201384.","journal-title":"Eur J Endocrinol"},{"key":"2071_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1530\/EJE-09-0012","volume":"160","author":"E Delgrange","year":"2009","unstructured":"Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009;160:747\u201352.","journal-title":"Eur J Endocrinol"},{"key":"2071_CR10","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","volume":"82","author":"A Colao","year":"1997","unstructured":"Colao A, Di Sarno A, Landi ML, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab. 1997;82:3574\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"2071_CR11","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","volume":"86","author":"A Di Sarno","year":"2001","unstructured":"Di Sarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001;86:5256\u201361.","journal-title":"J Clin Endocrinol Metab"},{"key":"2071_CR12","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1210\/jc.2007-2758","volume":"93","author":"M Ono","year":"2008","unstructured":"Ono M, Miki N, Kawamata T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008;93:4721\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"2071_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","volume":"17","author":"M Barake","year":"2014","unstructured":"Barake M, Evins AE, Stoeckel L, et al. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary. 2014;17:150\u20136.","journal-title":"Pituitary"},{"key":"2071_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1447-0594.2012.00871.x","volume":"13","author":"DK Miu","year":"2013","unstructured":"Miu DK, Yeung JC. Incidence of post-stroke delirium and 1-year outcome. Geriatr Gerontol Int. 2013;13:123\u20139.","journal-title":"Geriatr Gerontol Int"},{"key":"2071_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10143-015-0669-4","volume":"39","author":"E Kpelao","year":"2016","unstructured":"Kpelao E, Beketi KA, Moumouni AK, et al. Clinical profile of subdural hematoma: dangerousness of subacute subdural hematoma. Neurosurg Rev. 2016;39:237\u201340.","journal-title":"Neurosurg Rev"},{"key":"2071_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1592\/phco.29.1.64","volume":"29","author":"JR Bostwick","year":"2009","unstructured":"Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009;29:64\u201373.","journal-title":"Pharmacotherapy"},{"key":"2071_CR17","first-page":"88","volume":"26","author":"J Liu","year":"2014","unstructured":"Liu J, Sun J, Shen X, et al. Randomized controlled trial comparing changes in serum prolactin and weight among female patients with first-episode schizophrenia over 12 months of treatment with risperidone or quetiapine. Shanghai Arch Psychiatry. 2014;26:88\u201394.","journal-title":"Shanghai Arch Psychiatry"},{"key":"2071_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.psychres.2016.03.015","volume":"239","author":"YM Park","year":"2016","unstructured":"Park YM, Lee SH, Lee BH, et al. Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: a preliminary study. Psychiatry Res. 2016;239:184\u20139.","journal-title":"Psychiatry Res"},{"key":"2071_CR19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/106002800303700208","volume":"37","author":"AR Kunwar","year":"2003","unstructured":"Kunwar AR, Megna JL. Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine. Ann Pharmacother. 2003;37:206\u20138.","journal-title":"Ann Pharmacother"},{"key":"2071_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00213-002-1148-5","volume":"163","author":"C Sch\u00fcle","year":"2002","unstructured":"Sch\u00fcle C, Baghai T, Goy J, Bidlingmaier M, Strasburger C, Laakmann G. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Psychopharmacology. 2002;163:95\u2013101.","journal-title":"Psychopharmacology"},{"key":"2071_CR21","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/sj.npp.1300923","volume":"31","author":"DA Schmid","year":"2006","unstructured":"Schmid DA, Wichniak A, Uhr M, et al. Changes of sleep architecture spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology. 2006;31:832\u201344.","journal-title":"Neuropsychopharmacology"},{"key":"2071_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000477313","volume":"86","author":"G Chouinard","year":"2017","unstructured":"Chouinard G, Samaha AN, Chouinard VA, et al. Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. Psycother Psychosom. 2017;86:189\u2013219.","journal-title":"Psycother Psychosom"},{"key":"2071_CR23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000444220","volume":"97","author":"R Gupta","year":"2016","unstructured":"Gupta R, Gupta K, Tripathi AK, Bhatia MS, Gupta LK. Effect of mirtazapine treatment on serum levels of brain-derived neurotrophic factor and tumor necrosis factor-\u03b1 in patients of major depressive disorder with severe depression. Pharmacology. 2016;97:184\u20138.","journal-title":"Pharmacology"},{"key":"2071_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jad.2014.12.033","volume":"174","author":"H Li","year":"2015","unstructured":"Li H, Hong W, Zhang C, et al. IL-23 and TGF\u03b21 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode. J Affect Disord. 2015;174:361\u20136.","journal-title":"J Affect Disord"},{"key":"2071_CR25","first-page":"gmr15017502","volume":"15","author":"JL Wu","year":"2016","unstructured":"Wu JL, Qiao JY, Duan QH. Significance of TNF-\u03b1 and IL-6 expression in invasive pituitary adenomas. Genet Mol Res. 2016;15:gmr15017502.","journal-title":"Genet Mol Res"},{"key":"2071_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/FTD.0b013e31827e18d2","volume":"35","author":"AR Prossin","year":"2013","unstructured":"Prossin AR, Zalcman SS, Evans SJ, McInnis MG, Ellingrod VL. A pilot study investigating TNF-\u03b1 as a potential intervening variable of atypical antipsychotic associated metabolic syndrome in bipolar disorder. Ther Drug Monit. 2013;35:194\u2013202.","journal-title":"Ther Drug Monit"},{"key":"2071_CR27","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1530\/JOE-15-0451","volume":"228","author":"MV Recouvreux","year":"2016","unstructured":"Recouvreux MV, Camilletti MA, Rifkin DB, Diaz-Torga G. The pituitary TGF \u03b21 system as a novel target for the treatment of resistant prolactinomas. J Endocrinol. 2016;228:R73\u201383.","journal-title":"J Endocrinol"},{"key":"2071_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1530\/EJE-13-0231","volume":"169","author":"RS Auriemma","year":"2013","unstructured":"Auriemma RS, Pivonello R, Perone Y, et al. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013;169:359\u201366.","journal-title":"Eur J Endocrinol"},{"key":"2071_CR29","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S2213-8587(14)70212-8","volume":"3","author":"C Caputo","year":"2015","unstructured":"Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes Endocrinol. 2015;3:906\u201313.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-019-2071-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-019-2071-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-019-2071-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T23:03:09Z","timestamp":1592175789000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-019-2071-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,16]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2071"],"URL":"https:\/\/doi.org\/10.1186\/s13256-019-2071-2","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,16]]},"assertion":[{"value":"27 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This case report complies with the Declaration of Helsinki. Approval was also obtained from the Ethics Committee of Veron Clinic, Bras\u00edlia, Brazil.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"183"}}